SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is attracting significant investor attention as the company divests its non-core gaming division to sharpen its strategic focus on cloud and AI expansion, with the community actively debating the long-term impact of this capital reallocation. While some retail investors remain optimistic about the company's AI-driven growth potential, others are closely monitoring shareholder dilution concerns voiced by prominent investors regarding recent capital-raising activities.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors aggressively monitor for the 80th clinical event from the REGAL Phase 3 trial, fueling intense speculation regarding a potential buyout and short-covering momentum. The community remains deeply divided, with bulls pointing to survival plateaus as proof of efficacy while bears continue to challenge trial integrity and management's past communications.

TOSHI

TOSHI is trending as the community speculates on a potential short squeeze, fueled by bullish sentiment regarding future exchange listings and hopes that the token will reclaim previous highs. Investors are actively accumulating positions and monitoring order book activity, maintaining a strong conviction in the project's long-term potential despite recent volatility.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is drawing significant attention after disclosing a major partnership with Google to develop custom AI silicon, a deal that includes a significant warrant agreement. While the stock has seen high volatility, community sentiment is largely centered on whether this strategic move will drive long-term revenue growth or result in shareholder dilution.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is trending as investors react to a new $600 million at-the-market equity offering, sparking heated debate between those fearing share dilution and others viewing it as necessary capital to fuel data center demand. While some retail traders are aggressively shorting the stock in anticipation of further price declines, others are treating the dip as a long-term buying opportunity to gain exposure to AI-driven photonics.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending as investors weigh strong earnings and guidance against persistent price action volatility, while the community intensely debates potential buyout scenarios and institutional positioning ahead of upcoming pipeline catalysts.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors digest a strong earnings report that highlighted accelerating global revenue and increased guidance, while buyout rumors continue to fuel speculation about potential interest from large pharmaceutical players. The community is actively debating the company's valuation as a standalone growth story versus its appeal as a premium acquisition target for big pharma looking to bolster their neurology and immunology portfolios.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is facing intense selling pressure following a disappointing full-year guidance cut and the unexpected departure of its CFO and CMO, despite a positive earnings beat. Community sentiment remains deeply polarized as investors debate whether the current price represents a long-term buying opportunity or a deeper structural failure.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

The biotech sector is trending as investors rotate into healthcare, driven by a surge in M&A activity and positive sentiment regarding clinical trial breakthroughs and regulatory catalysts. Community discussion centers on identifying undervalued assets and monitoring institutional accumulation as biotech ETFs reach key technical resistance levels.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

XBI is trending as investors monitor sector rotations and the anticipation of upcoming biotech catalyst readouts, while community members actively debate the volatility of small-cap biotech names and potential buyout opportunities. Speculation regarding institutional accumulation and regulatory milestones for individual companies remains a central focus for the sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vera Therapeutics is trending as investors weigh the potential for a transformative buyout or significant re-rating ahead of the upcoming ORIGIN 3 data release and BLA submission. The community is actively debating the company's valuation against competitive IgAN treatments, with many bullish on its dual BAFF/APRIL inhibitor profile and strong institutional backing despite recent price volatility.

VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics

Equity

Vera Therapeutics' Trutakna received an early, fast-tracked approval from the FDA to reduce proteinuria in adults with primary IgA Nephropathy whose health is at risk of deterioration. 


Why Is Vera Therapeutics Stock Gaining Tuesday?

Vera Therapeutics (VERA) stock jumps 9% following FDA accelerated approval for its kidney disease drug Trutakna. Full analysis here.read more...

VERA Stock Rallies Ahead Of High-Stakes FDA Decision On Lead Kidney Disease Drug – Retail Sees 35% Potential Upside

The U.S. Food and Drug Administration is set to announce its decision on Atacicept later on Monday, paving the way for the potential commercialization of the drug in the U.S.

Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment

The biotech moves a step closer to full approval in IgAN as regulators agree to an accelerated timeline for key kidney function data review.

Pictet Asset Management Holding SA Cuts Stake in Vera Therapeutics, Inc. $VERA

Pictet Asset Management Holding SA cut its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 3.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,392,421 shares of the company's stock after sellin...

Vera Therapeutics (VERA) to Release Earnings on Tuesday

Vera Therapeutics (NASDAQ:VERA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...

Vera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 22,951 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 22,951 shares of the company's stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55. Following the completion of the transaction, the...

Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of "Moderate Buy" by Analysts

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and t...

Vera Therapeutics (NASDAQ:VERA) CEO Sells $1,010,991.55 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 22,951 shares of the company's stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total value of $1,010,991.55. Following the transaction, the chief executive...

AMI Asset Management Corp Makes New $1.44 Million Investment in Vera Therapeutics, Inc. $VERA

AMI Asset Management Corp bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange...

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$1.61	--	--	N/A
Q2 '26	-$1.56	-$1.52	2.66%	BEAT
Q1 '26	-$1.33	-$1.69	-27.22%	MISSED
Q4 '25	-$1.34	-$1.39	-3.84%	MISSED
Q3 '25	-$1.16	-$1.26	-8.39%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings